

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

At consultation stakeholders noted that people with protected characteristics have much lower rates of participation in clinical trials, and that if the intervention were approved it would bring the treatment of those patients outside of trials almost to the level of quality of those within trials.

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

The opportunity for people with protective characteristics to access promising treatments in clinical trials is not considered to be an equalities issue that requires specific consideration by the evaluation committee. However it is anticipated that the appraisal will consider whether the trial population is representative of the people who would have this medicine in clinical practice and how the trial estimates of clinical effectiveness are generalisable to NHS clinical practice.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No	

Approved by Associate Director (name):...Richard

Diaz.....

Date: 06 May 2025